share_log

Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXU) Shares Acquired by Wolverine Asset Management LLC

Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXU) Shares Acquired by Wolverine Asset Management LLC

鳳凰生物科技收購公司(納斯達克代碼:PBAXU)被金剛狼資產管理公司收購的股票
Defense World ·  2022/11/01 07:43

Wolverine Asset Management LLC lifted its position in shares of Phoenix Biotech Acquisition Corp. (NASDAQ:PBAXU – Get Rating) by 126.6% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 22,366 shares of the company's stock after buying an additional 12,495 shares during the quarter. Wolverine Asset Management LLC's holdings in Phoenix Biotech Acquisition were worth $225,000 at the end of the most recent quarter.

據最近提交給美國證券交易委員會的文件顯示,金剛狼資產管理公司在第二季度將其在鳳凰生物科技收購公司(納斯達克代碼:PBAXU-GET Rating)的股票持倉量提高了126.6%。該基金在本季度額外購買了12,495股後,持有該公司22,366股股票。金剛狼資產管理公司在最近一個季度末收購的菲尼克斯生物科技公司所持股份價值22.5萬美元。

Separately, Spartan Fund Management Inc. purchased a new stake in shares of Phoenix Biotech Acquisition during the 1st quarter worth about $629,000.

另外,斯巴達基金管理公司(Spartan Fund Management Inc.)在第一季度購買了菲尼克斯生物科技收購的新股份,價值約62.9萬美元。

Get
到達
Phoenix Biotech Acquisition
收購鳳凰生物科技
alerts:
警報:

Phoenix Biotech Acquisition Price Performance

鳳凰生物科技收購價格表現

Phoenix Biotech Acquisition stock opened at $10.15 on Tuesday. The stock's 50 day moving average price is $10.11 and its 200 day moving average price is $10.09. Phoenix Biotech Acquisition Corp. has a one year low of $9.94 and a one year high of $11.21.

鳳凰生物科技收購股票週二開盤報10.15美元。該股的50日移動均線價格為10.11美元,200日移動均線價格為10.09美元。菲尼克斯生物科技收購公司的股價一年來最低為9.94美元,一年最高為11.21美元。

Phoenix Biotech Acquisition Profile

鳳凰生物科技收購簡介

(Get Rating)
(獲取評級)

Phoenix Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It engages in identifying and acquiring a business that focuses on the healthcare or healthcare related industries in the United States and Europe.

菲尼克斯生物科技收購公司沒有重大業務。公司擬與一家或者多家企業實施合併、換股、資產收購、購股、重組或者類似的業務合併。它致力於識別和收購一家專注於美國和歐洲的醫療保健或醫療保健相關行業的企業。

Featured Stories

專題報道

  • Get a free copy of the StockNews.com research report on Phoenix Biotech Acquisition (PBAXU)
  • Here's Why Harley-Davidson is Roaring Higher
  • As Mega Caps Get Crushed, This Mid Cap Tech Stock Is Crushing It
  • Is The Meta Platforms Stock Meltdown a Rare Buying Opportunity?
  • Why Investors Are Suddenly Excited About Vaxcyte
  • Saia Stock Is Ready To Switch Gears And Move Higher
  • 免費獲取StockNews.com關於鳳凰生物科技收購的研究報告(PBAXU)
  • 這就是為什麼哈雷-戴維森公司在咆哮
  • 隨着Mega Caps被壓垮,這隻中型股科技股正在壓垮它
  • Meta平臺股票崩盤是難得的買入機會嗎?
  • 為什麼投資者突然對Vaxcell感到興奮
  • SAIA股票已做好換擋走高的準備

Receive News & Ratings for Phoenix Biotech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phoenix Biotech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.

獲得《鳳凰生物科技收購日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對菲尼克斯生物技術收購和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論